JP2019516789A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516789A5
JP2019516789A5 JP2019510578A JP2019510578A JP2019516789A5 JP 2019516789 A5 JP2019516789 A5 JP 2019516789A5 JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019516789 A5 JP2019516789 A5 JP 2019516789A5
Authority
JP
Japan
Prior art keywords
patent document
fulvestrant
international
publication
international publication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019510578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031376 external-priority patent/WO2017193048A1/en
Publication of JP2019516789A publication Critical patent/JP2019516789A/ja
Publication of JP2019516789A5 publication Critical patent/JP2019516789A5/ja
Priority to JP2021118471A priority Critical patent/JP7312523B2/ja
Priority to JP2023086732A priority patent/JP2023109959A/ja
Pending legal-status Critical Current

Links

JP2019510578A 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法 Pending JP2019516789A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021118471A JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662332842P 2016-05-06 2016-05-06
US62/332,842 2016-05-06
US201662420555P 2016-11-10 2016-11-10
US62/420,555 2016-11-10
PCT/US2017/031376 WO2017193048A1 (en) 2016-05-06 2017-05-05 Fulvestrant formulations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118471A Division JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019516789A JP2019516789A (ja) 2019-06-20
JP2019516789A5 true JP2019516789A5 (enExample) 2020-04-30

Family

ID=58709642

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019510578A Pending JP2019516789A (ja) 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Country Status (15)

Country Link
US (2) US20190134059A1 (enExample)
EP (1) EP3452011A1 (enExample)
JP (3) JP2019516789A (enExample)
KR (1) KR102438425B1 (enExample)
CN (1) CN109310621A (enExample)
AU (2) AU2017261321B2 (enExample)
CA (1) CA3022834A1 (enExample)
CO (1) CO2018013257A2 (enExample)
IL (2) IL285928B2 (enExample)
MA (1) MA44862A (enExample)
MX (2) MX2018013414A (enExample)
MY (1) MY205661A (enExample)
UA (1) UA125514C2 (enExample)
WO (1) WO2017193048A1 (enExample)
ZA (1) ZA201807031B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法
WO2022100750A1 (zh) * 2020-11-16 2022-05-19 北京厚燊维康科技有限责任公司 可用于光动力治疗或诊断的制剂
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2001087262A2 (en) 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EP1406662A1 (en) * 2001-07-07 2004-04-14 AstraZeneca AB Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116619D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
JP2003298516A (ja) 2002-03-29 2003-10-17 Fujitsu Ltd 波長分散補償装置
JP5513713B2 (ja) * 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
CN101237857A (zh) 2005-05-09 2008-08-06 生物领域医疗公司 使用微球和非离子型造影剂的组合物和方法
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101108168B (zh) * 2007-08-03 2010-12-08 西安力邦医药科技有限责任公司 一种氟维司群缓释微球的制备方法
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
TW201016220A (en) * 2008-10-31 2010-05-01 Scinopharm Taiwan Ltd Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof
EP2442789A1 (en) 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
US20130280330A9 (en) * 2009-07-31 2013-10-24 Xi'an Libang Medical Technology Co., Ltd. Microsphere drug carrier, preparation method, composition and use thereof
CN102264372B (zh) * 2009-08-31 2012-07-11 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
WO2012021791A2 (en) 2010-08-13 2012-02-16 Scidose Llc Aqueous formulation with improved stability
CA2811258C (en) 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
EP3925625A1 (en) 2011-01-09 2021-12-22 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
CA2836831C (en) * 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102915088A (zh) 2011-08-03 2013-02-06 鸿富锦精密工业（深圳）有限公司 资料存储器固定装置
CA2869377C (en) 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US11179468B2 (en) * 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
US20160287601A1 (en) * 2013-10-03 2016-10-06 Millennium Pharmaceuticals, Inc. Enhanced treatment regimens using pi3k inhibitors
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2016004369A1 (en) 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法

Similar Documents

Publication Publication Date Title
JP2019502892A5 (enExample)
JP2016153424A5 (enExample)
JP2014235432A5 (enExample)
JP2016135874A5 (enExample)
JP2014513484A5 (enExample)
JP2014528601A5 (enExample)
JP2014138100A5 (enExample)
JP2015127343A5 (enExample)
JP2018127649A5 (enExample)
CN109415361A (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP2017061637A5 (enExample)
JP2017524633A5 (enExample)
CN109548403A (zh) Galunisertib的晶型及其制备方法和用途
JP2016506003A5 (enExample)
JP2019527311A5 (enExample)
JP2010536929A5 (enExample)
CN109310676A (zh) 一种苯酚衍生物和依托咪酯的药物组合物、药物制剂及其用途
JP2015042663A5 (enExample)
JP2014508098A5 (enExample)
JP2013535391A5 (enExample)
JP2021502362A5 (enExample)
CN109476662A (zh) 一种jak1选择性抑制剂的新晶型及其制备方法和用途
JP2019521402A5 (enExample)
CN111315741A (zh) 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法
CN109311831A (zh) 4-苯基噻唑衍生物的晶型及其制备方法